WAVE Life Sciences Ltd. (WVE) Announces Earnings Results
WAVE Life Sciences Ltd. (NASDAQ:WVE) released its quarterly earnings data on Wednesday. The company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.14, Bloomberg Earnings reports. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.73 million. WAVE Life Sciences had a negative net margin of 3,172.14% and a negative return on equity of 48.16%.
WAVE Life Sciences (NASDAQ WVE) remained flat at $18.10 during mid-day trading on Thursday. 71,449 shares of the stock were exchanged. The company’s 50-day moving average is $18.92 and its 200-day moving average is $23.27. The company’s market capitalization is $501.68 million. WAVE Life Sciences has a one year low of $15.15 and a one year high of $40.15.
In other news, insider Michael A. Panzara sold 7,414 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $16.67, for a total value of $123,591.38. Following the completion of the transaction, the insider now owns 15,336 shares of the company’s stock, valued at $255,651.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 53.00% of the company’s stock.
A number of research firms have commented on WVE. Zacks Investment Research downgraded shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Jefferies Group LLC set a $42.00 price objective on shares of WAVE Life Sciences and gave the company a “buy” rating in a report on Thursday, June 8th. ValuEngine downgraded shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, June 16th. Finally, JMP Securities reiterated an “outperform” rating and issued a $40.00 price objective on shares of WAVE Life Sciences in a report on Friday, June 9th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $42.00.
WAVE Life Sciences Company Profile
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Stock Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related stocks with our FREE daily email newsletter.